Osteosarcoma associated with Diamond-Blackfan anaemia: A case of a child receiving growth hormone therapy

Sarcoma

Volumn 8, Issue 1, 2004, Pages 47-49

  Lee, Robert S ^a   Higgs, Deborah ^a   Haddo, Omar ^a   Pringle, Jean ^a   Briggs, Timothy W R ^a  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GROWTH HORMONE; METHOTREXATE;

ARTICLE; BLACKFAN DIAMOND ANEMIA; BONE PROSTHESIS; CANCER SURGERY; CANCER SUSCEPTIBILITY; CASE REPORT; CHILD; CLINICAL FEATURE; FEMALE; FEMUR TUMOR; HEMATOLOGIC MALIGNANCY; HORMONAL CARCINOGENESIS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SHORT STATURE; SOLID TUMOR;

EID: 1842610485     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140410001679266     Document Type: Article

References (9)

1. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard, LM, Clark JI, Vlachos A. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan registry. J Pediatr Hematol Oncol 2001; 23: 39-44.
2. Aquino VM, Buchanan GR. Ostoegenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. J Pediatr Hematol Oncol 1996; 18: 230-2.
3. Willig T-N, Niemeyer CM, Leblanc T, et al. Identification of new prognosis factors from the clinical and epidemiological analysis of a registry of 229 Diamond-Blackfan anemia patients. Pediatr Res 1999; 46: 553-61.
4. Darendeliler F, Bundak R, Eryilmaz SK, Gunoz H, Bas F, Saka N. Follow-up height after discontinuation of growth hormone treatment in children with intrauterine growth retardation. J Pediatr Endocrinol Metab 2002; 15: 795-800.
5. Hall MB, Sclar AG, Gardner DF. Albright's syndrome with reactivation of fibrous dysplasia secondary to pituitary adenome and further complicated by osteogenic sarcoma. Report of a case. Oral Surg Oral Med Oral Pathol 1984; 57: 616-9.
6. Scheven BA, Hamilton NJ, Fakkeldij TM, Duursma SA. Effects of recombinant human insulin-like growth factor I and II (IGF-I/-II) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regul 1991; 1: 160-7.
7. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. Inhibition of growth of human osteosarcomas by antagonist of growth hormone-releasing hormone. J Natl Cancer Inst 1995; 87: 1787-94.
8. Brackowski R, Schally AV, Plonowski V, Varga JL, Groot K, Krup M, Armatis P. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell line in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 2002; 95: 1735-45.
9. Hauben EI, Arends JJ, Vandenbrouke JP, van Asperen C, van Marck E, Hogendoorn, PCW. Osteosarcoma subtypes in osteosarcoma patients with multiple primary malignancies. Can rare subtypes be indicative for cancer syndromes related with osteosarcoma? Sarcoma 2002; 6 (Suppl): 13-18 (EMSOS abstract B22).